Icosapent Ethyl Decreases Cardiovascular Event Risk in Metab

Icosapent ethyl in patients with metabolic syndrome without diabetes receiving statin therapy can reduce risk for cardiovascular events.

Related Keywords

, European Heart Journal , Cardiovascular Events , Icosapent Ethyl Trial ,